Twist Bioscience Stock Forecast, Price & News

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Twist Bioscience in the last twelve months. There are currently 1 sell rating, 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Twist Bioscience stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TWST, but not buy additional shares or sell existing shares.
View analyst ratings for Twist Bioscience or view top-rated stocks.

Wall Street analysts have given Twist Bioscience a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Twist Bioscience wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Twist Bioscience saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 3,580,000 shares, an increase of 39.8% from the February 28th total of 2,560,000 shares. Based on an average daily trading volume, of 985,200 shares, the days-to-cover ratio is currently 3.6 days.
View Twist Bioscience's Short Interest.

Twist Bioscience is scheduled to release its next quarterly earnings announcement on Thursday, May 6th 2021.
View our earnings forecast for Twist Bioscience.

Twist Bioscience Co. (NASDAQ:TWST) issued its quarterly earnings results on Wednesday, February, 3rd. The company reported ($0.72) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.74) by $0.02. The firm had revenue of $28.16 million for the quarter, compared to analyst estimates of $25.26 million. Twist Bioscience had a negative trailing twelve-month return on equity of 44.62% and a negative net margin of 155.31%.
View Twist Bioscience's earnings history.

Twist Bioscience's stock was trading at $28.20 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, TWST stock has increased by 379.6% and is now trading at $135.24.
View which stocks have been most impacted by COVID-19.

Twist Bioscience issued an update on its FY 2021 After-Hours earnings guidance on Thursday, February, 4th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $110-118 million, compared to the consensus revenue estimate of $116.02 million.

5 brokerages have issued 12-month price targets for Twist Bioscience's shares. Their forecasts range from $100.00 to $200.00. On average, they expect Twist Bioscience's share price to reach $137.50 in the next year. This suggests a possible upside of 1.7% from the stock's current price.
View analysts' price targets for Twist Bioscience or view top-rated stocks among Wall Street analysts.

44 employees have rated Twist Bioscience CEO Emily Leproust on Glassdoor.com. Emily Leproust has an approval rating of 83% among Twist Bioscience's employees.

Some companies that are related to Twist Bioscience include Novavax (NVAX), Bio-Techne (TECH), Novozymes A/S (NVZMY), argenx (ARGX), QIAGEN (QGEN), Repligen (RGEN), Neurocrine Biosciences (NBIX), CRISPR Therapeutics (CRSP), Fate Therapeutics (FATE), Acceleron Pharma (XLRN), Halozyme Therapeutics (HALO), Denali Therapeutics (DNLI), Vir Biotechnology (VIR), Kodiak Sciences (KOD) and Adaptive Biotechnologies (ADPT).
View all of TWST's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Twist Bioscience investors own include CrowdStrike (CRWD), Pfizer (PFE), DocuSign (DOCU), Intel (INTC), NVIDIA (NVDA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), JD.com (JD), Tesla (TSLA) and Twilio (TWLO).

(TWST) raised $75 million in an initial public offering (IPO) on Wednesday, October 31st 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. J.P. Morgan and Cowen acted as the underwriters for the IPO and Allen & Company and Baird were co-managers.

Twist Bioscience trades on the NASDAQ under the ticker symbol "TWST."

Twist Bioscience's stock is owned by a variety of institutional and retail investors. Top institutional investors include Wolff Wiese Magana LLC (0.01%), Phoenix Wealth Advisors (0.01%), Pacer Advisors Inc. (0.00%) and AdvisorNet Financial Inc (0.00%). Company insiders that own Twist Bioscience stock include Bill Peck, Emily M Leproust, James M Thorburn, Keith Crandell, Mark Daniels, Nicolas Barthelemy, Patrick John Finn, Patrick Weiss, Paula Green, Robert Chess and William Banyai.
View institutional ownership trends for Twist Bioscience.

TWST stock was sold by a variety of institutional investors in the last quarter, including Pacer Advisors Inc.. Company insiders that have sold Twist Bioscience company stock in the last year include Emily M Leproust, James M Thorburn, Keith Crandell, Mark Daniels, Nicolas Barthelemy, Patrick John Finn, Patrick Weiss, Paula Green, Robert Chess, and William Banyai.
View insider buying and selling activity for Twist Bioscience or view top insider-selling stocks.

TWST stock was acquired by a variety of institutional investors in the last quarter, including Wolff Wiese Magana LLC, AdvisorNet Financial Inc, and Phoenix Wealth Advisors.
View insider buying and selling activity for Twist Bioscience or or view top insider-buying stocks.

Shares of TWST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of TWST stock can currently be purchased for approximately $135.24.

Twist Bioscience has a market capitalization of $6.58 billion and generates $90.10 million in revenue each year. The company earns $-139,930,000.00 in net income (profit) each year or ($3.00) on an earnings per share basis.

Twist Bioscience employs 525 workers across the globe.

The official website for Twist Bioscience is www.twistbioscience.com.

Twist Bioscience is headquartered at 681 GATEWAY BLVD., SOUTH SAN FRANCISCO CA, 94080.

Twist Bioscience's mailing address is 681 GATEWAY BLVD., SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 800-719-0671 or via email at [email protected]